Skip to main content
In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global perspectives regarding treatment, equity, and patient advocacy in lung cancer.  ...
On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share recent advances in lung cancer research and ways to raise awareness of this disease for both the public and t...
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell...
Oncology Data Advisor® · Lung Cancer Awareness Month: Global Perspectives With MedNews Week and Oncology Data Advisor In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global ...
Oncology Data Advisor® · Lung Cancer Awareness Month With Waqas Haque, Samuel Kareff, & Matthew Hadfield On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Fellows Forum joined forces to share recent re...
Oncology Data Advisor® · World Cancer Research Day With Samuel Kareff, Maria Badillo, Matthew Hadfield, and Alankrita Taneja In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined...
The FDA has approved repotrectinib (Augtyro™, Bristol Myers Squibb Company) for locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). This is the first approval for the next-generation ROS1/TRK tyrosine kinase inhibitor (TK...
The FDA has approved pembrolizumab (Keytruda®, Merck) for non–small cell lung cancer (NSCLC) as neoadjuvant treatment in combination with platinum-containing chemotherapy, and with continuation of single-agent pembrolizumab as post-surgical adjuvant ...
The FDA has approved encorafenib (Braftovi®, Array BioPharma Inc.) with binimetinib (Mektovi®, Array BioPharma Inc.) for adult patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test...